Effects of lapatinib monotherapy: Results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck
British Journal of Cancer,  Clinical Article

del Campo JM et al. –Short-term lapatinib monotherapy did not demonstrate apoptotic changes, but provided evidence of clinical activity in locally advanced SCCHN, and warrants further investigation in this disease.

Methods

  • 107 therapy-naive patients with locally advanced SCCHN were randomised (2?:?1) to receive lapatinib or placebo for 2–6 weeks before chemoradiation therapy (CRT)
  • Endpoints included apoptosis and proliferation rates, clinical response, and toxicity

Results
  • Versus placebo, lapatinib monotherapy did not significantly increase apoptosis detected by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end labelling or caspase-3 assays
  • Statistically significant decrease in proliferation using Ki67 assay was observed (P=0.030)
  • In subset of 40 patients that received 4 weeks of lapatinib or placebo, ORR was 17% (n=4/24) vs 0% (n=0/16)
  • In lapatinib single-agent responders, all had EGFR overexpression, 50% had EGFR amplification, and 50% had HER2 expression by immunohistochemistry (including one patient with HER2 amplification)
  • These patients showed variable modulation of apoptosis, proliferation, and phosphorylated EGFR on drug treatment
  • Following CRT, there was statistically non-significant difference in ORR between lapatinib (70%) and placebo (53%)
  • No clear correlation between changes in apoptosis or proliferation and response to chemoradiation
  • Mucosal inflammation, asthenia, odynophagia, and dysphagia were most commonly reported AEs with lapatinib

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

<

Most Popular Oncology Articles

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Make smarter career moves with less time.

Sign up for our free job placement service today and have a dedicated career consultant help locate the right physician job for you!
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List